November 8, 2012 / 6:57 AM / 5 years ago

BRIEF-Galapagos says Phase IIa trial shows promising results

BRUSSELS, Nov 8 (Reuters) - Galapagos NV : * Glpg0634 phase 2a multicenter trial shows dose-response, confirms excellent

safety and significant clinical benefit in rheumatoid arthritis patients * Drug would treat rheumatoid arthritis

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below